论文部分内容阅读
目的:观察肝动脉栓塞化疗术(TACE)联合自体细胞因子诱导的杀伤细胞(CIK)过继性免疫治疗对原发性肝癌(HCC)的效果。方法:选择确诊HCC 46例,随机分为观察组24例和对照组22例。对照组采用TACE治疗;观察组在TACE间歇期进行CIK细胞治疗。比较两组术后生活质量(QOL)改善情况、1年及3年生存率。结果:观察组QOL改善率显著高于对照组(P<0.05);观察组1年生存率、3年生存率均显著高于对照组(P<0.05)。结论:TACE联合CIK细胞免疫治疗可以提高HCC患者的生活质量,延长生存期。
Objective: To observe the effect of hepatic artery embolization chemotherapy (TACE) combined with autologous cytokine-induced killer (CIK) adoptive immunotherapy on primary hepatocellular carcinoma (HCC). Methods: Forty-six cases with confirmed HCC were randomly divided into observation group (24 cases) and control group (22 cases). The control group was treated with TACE; the observation group was treated with CIK cells during the interval of TACE. The postoperative quality of life (QOL) improvement, 1-year and 3-year survival rates were compared between the two groups. Results: The QOL improvement rate in the observation group was significantly higher than that in the control group (P<0.05). The one-year survival rate and three-year survival rate in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: TACE combined with CIK cell immunotherapy can improve the quality of life and prolong survival of HCC patients.